Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

March 1, 2026

Conditions
Total Shoulder ArthroplastyReverse Total Shoulder Arthroplasty
Interventions
DRUG

Liposomal bupivacaine

Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).

DRUG

Bupivacaine

Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.

Trial Locations (1)

60076

RECRUITING

NorthShore University HealthSystem, Skokie

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Endeavor Health

OTHER

lead

Johnny K. Lee

OTHER